NEW YORK (GenomeWeb) – Roche said today that it has completed a previously announced $1.9 billion acquisition of Flatiron Health, a provider of electronic health record software with a focus on oncology.
Flatiron curates and develops real-world evidence for cancer research. It has a network of community oncology practices and academic medical centers across the US and has designed a technology platform that enables cancer researchers and care providers to learn from the experience of every patient, Roche said.
It noted that Flatiron partners with more than 265 community cancer clinics, six major academic research centers, and 14 therapeutic oncology companies.
Flatiron will continue to operate as a separate legal entity and retain its current business model, network of partners, and overall objectives, Roche said. It will also preserve the integrity of segregated patient protected health information and retain dedicated sales and marketing, provider-facing, and life-science business activities.
The acquisition allows both companies to accelerate progress toward data-driven personalized healthcare in cancer, Roche said. Prior to the acquisition, Roche held a nearly 13 percent stake in the New York City-based firm.